email article
Thirteen new rare gene variants in loci related to synaptic function and neuronal development were associated with Alzheimer s disease.
(Alzheimer s and Dementia)
In an unusual
JAMA op-ed, three members of the FDA s advisory committee reviewing aducanumab took another shot at the controversial Alzheimer s drug candidate, laying out reasons why aducanumab shouldn t be approved.
The FDA rejected Acadia Pharmaceuticals bid to expand indications for pimavanserin (Nuplazid) to include hallucinations and delusions associated with dementia-related psychosis. The notice came a month after the agency first alerted the company to potential snags with its application.
Approved: viloxazine extended-release capsules (Qelbree), a non-stimulant ADHD treatment for children ages 6 to 17 and the first new drug for the disorder in over a decade, Supernus Pharmaceuticals said.